This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): IMC-1121B, LY3009806, Sairamuza (Japan)
Description: IMC-1121B is a fully human monoclonal antibody that is designed to bind to the VEGFR-2 found on tumor vasculature, thereby inhibiting certain ligands known as vascular endothelial growth factors from binding to and activating the receptor. This action blocks a signaling pathway key to new blood vessel formation in growing tumors, which has been shown to starve tumors of their nutrient supply and result in significant tumor growth inhibition in pre-clinical models.
Deal Structure: IMC-1121B was selected from a Dyax Phage Display library. In 1997, Dyax licensed its Ladner Phage Display patents to CAT and CAT granted certain limited rights to Dyax in relation to its Phage Display technology patents. In 2003, CAT and Dyax agreed to expand this access and to grant freedom to operate under each other's Phage Display technology patents. CAT granted Dyax worldwide licences for research purposes accessing all the Phage Display technology patents controlled by CAT and options for licences to develop therapeutic and diagnostic antibody products under CAT's patents. In return CAT will receive milestone and royalty payments on antibody products successfully developed by Dyax and its licensees.
CAT was acquired by AstraZeneca in 2006.
In November 2008 Eli Lilly completed the acquisition of ImClone Systems.
Dyax and Shire
In November 2015, Shire and Dyax announced that Shire will acquire Dyax for $37.30 in cash per Dyax share, for aggregate...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC Shire Pharmaceuticals Group PLC
Additional information available to subscribers only: